Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant settings, and how to apply this information into practice with a patient-centric approach.
Provided by the National Comprehensive Cancer Network in partnership with The France Foundation
This program is designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with NSCLC.
Following this program, participants should be able to:
- Recall the importance of testing for specific biomarkers in determining appropriate therapy for individual patients with NSCLC before and after surgery
- Explain the latest guidelines and clinical data on the role of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant settings
- Compare and contrast different PD-1/PD-L1 inhibitor options available for neoadjuvant and adjuvant therapy in resectable NSCLC
- Identify strategies to prevent, monitor, and manage treatment-related adverse events
Debora Bruno, MD, MS
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Matthew Gubens, MD, MS
UCSF Helen Diller Family Comprehensive Cancer Center
Sandip Patel, MD
UC San Diego Moores Cancer Center
Beth Sandy, MSN, CRNP
Abramson Cancer Center at the University of Pennsylvania
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Debora Bruno, MD, MS
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Eli Lilly and Company: Consulting Fee
Mirati Therapeutics, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Syneos Health: Consulting Fee
Matthew Gubens, MD, MS
Amgen Inc.: Grant/Research Support
AnHeart Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Atreca, Inc.: Consulting Fee
Cardinal Health: Consulting Fee
Genzyme: Consulting Fee
Genentech/Roche: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Guardant Health: Consulting Fee
Johnson & Johnson: Grant/Research Support
Invitae Corporation: Consulting Fee
iTeos Therapeutics: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
OncoMed Pharmaceuticals: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
Summit Therapeutics Inc.: Consulting Fee
Surface Oncology: Consulting Fee
Trizell Ltd: Grant/Research Support
Sandip Patel, MD
Amgen Inc.: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
AstraZeneca Pharmaceuticals LP/MedImmune Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Certis Oncology: Scientific Advisor
Eli Lilly and Company: Grant/Research Support; Scientific Advisor
Fate Therapeutics: Grant/Research Support
Jazz Pharmaceuticals Inc.: Scientific Advisor
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Grant/Research Support
Illumina, Inc.: Scientific Advisor
Iovance Biotherapeutics, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
Rakuten Medical, Inc.: Scientific Advisor
Roche Laboratories, Inc./Genentech, Inc.: Grant/Research Support
SQZ Biotechnologies Company: Grant/Research Support
Tempus Labs, Inc.: Scientific Advisor
Beth Sandy, MSN, CRNP
AbbVie, Inc.: Consulting Fee
Amgen Inc.: Product/Speakers Bureau
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Janssen Pharmaceutica Products, LP: Consulting Fee
Eli Lilly and Company: Product/Speakers Bureau
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
Takeda Pharmaceuticals North America, Inc.: Product/Speakers Bureau
NCCN and The France Foundation Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.75 contact hours.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credit. Approval is valid until August 9, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 1.75 AAPA Category 1 CME credit
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC contact hours
- 1.75 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing